MedTrace Logo

Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury

NCT04998370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 366

Last updated 2025-12-12

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the association between hemoglobin levels in the cerebrospinal fluid (CSF-Hb) and the occurrence of secondary brain injury in patients after aneurysmal subarachnoid hemorrhage (SAH-SBI) during the first 14 days after bleeding.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal
  • Vasospasm
  • Delayed Cerebral Ischemia
  • Delayed Ischemic Neurological Deficit

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Michael Hugelshofer, MD MSc · University Hospital and University of Zurich, Department of Neurosurgery

  • Kevin Akeret, MD/PhD · University Hospital and University of Zurich, Department of Neurosurgery

  • Dominik J Schaer, MD · University Hospital and University of Zurich, Department of Internal Medicine

  • Raphael M Buzzi, MD/PhD · University Hospital and University of Zurich, Department of Internal Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2024-09-30
Completion
2024-10-01

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04998370 on ClinicalTrials.gov